Chemistry and biology of dihydroisoxazole derivatives: Selective inhibitors of human transglutaminase 2

Kihang Choi, Matthew Siegel, Justin L. Piper, Liya Yuan, Eun Cho, Pavel Strnad, Bishr Omary, Keith M. Rich, Chaitan Khosla

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

3-Halo-4,5-dihydroisoxazoles are attractive warheads for the selective inhibition of nucleophilic active sites in biological systems. A series of 3-bromo-4,5-dihydroisoxazole compounds were prepared and tested for their ability to irreversibly inhibit human transglutaminase 2 (TG2), an enzyme that plays an important role in the pathogenesis of diverse disorders including Celiac Sprue and certain types of cancers. Several compounds showed high specificity for human TG2 (kinh/KI > 2000 min -1M-1) but essentially no reactivity (k < 1 min -1M-1) toward physiological thiols such as glutathione. The pharmacokinetic and pharmacodynamic properties of a prototype dihydroisoxazole inhibitor, 1b, were evaluated; in mice the compound showed good oral bioavailability, short serum half-life and efficient TG2 inhibition in small intestinal tissue, and low toxicity. It also showed excellent synergism with N,N′-bis(2-chloroethyl)-N-nitrosourea (BCNU, carmustine) against refractory glioblastoma tumors in mice. A fluorescent dihydroisoxazole inhibitor 5 facilitated microscopic visualization of TG2 endocytosis from the extracellular surface of HCT-116 cells. Together, these findings demonstrate the promise of dihydroisoxazole compounds as probes for the biology of TG2 and its role in human disease.

Original languageEnglish
Pages (from-to)469-475
Number of pages7
JournalChemistry and Biology
Volume12
Issue number4
DOIs
Publication statusPublished - 2005 Apr 1

Fingerprint

Derivatives
Carmustine
Pharmacodynamics
HCT116 Cells
Pharmacokinetics
Celiac Disease
Biological systems
Glioblastoma
Endocytosis
Sulfhydryl Compounds
Refractory materials
Biological Availability
Glutathione
Half-Life
Toxicity
Tumors
Catalytic Domain
Neoplasms
Visualization
transglutaminase 2

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Chemistry and biology of dihydroisoxazole derivatives : Selective inhibitors of human transglutaminase 2. / Choi, Kihang; Siegel, Matthew; Piper, Justin L.; Yuan, Liya; Cho, Eun; Strnad, Pavel; Omary, Bishr; Rich, Keith M.; Khosla, Chaitan.

In: Chemistry and Biology, Vol. 12, No. 4, 01.04.2005, p. 469-475.

Research output: Contribution to journalArticle

Choi, K, Siegel, M, Piper, JL, Yuan, L, Cho, E, Strnad, P, Omary, B, Rich, KM & Khosla, C 2005, 'Chemistry and biology of dihydroisoxazole derivatives: Selective inhibitors of human transglutaminase 2', Chemistry and Biology, vol. 12, no. 4, pp. 469-475. https://doi.org/10.1016/j.chembiol.2005.02.007
Choi, Kihang ; Siegel, Matthew ; Piper, Justin L. ; Yuan, Liya ; Cho, Eun ; Strnad, Pavel ; Omary, Bishr ; Rich, Keith M. ; Khosla, Chaitan. / Chemistry and biology of dihydroisoxazole derivatives : Selective inhibitors of human transglutaminase 2. In: Chemistry and Biology. 2005 ; Vol. 12, No. 4. pp. 469-475.
@article{7aaa000ab32d4e3690e68357a1b3cabc,
title = "Chemistry and biology of dihydroisoxazole derivatives: Selective inhibitors of human transglutaminase 2",
abstract = "3-Halo-4,5-dihydroisoxazoles are attractive warheads for the selective inhibition of nucleophilic active sites in biological systems. A series of 3-bromo-4,5-dihydroisoxazole compounds were prepared and tested for their ability to irreversibly inhibit human transglutaminase 2 (TG2), an enzyme that plays an important role in the pathogenesis of diverse disorders including Celiac Sprue and certain types of cancers. Several compounds showed high specificity for human TG2 (kinh/KI > 2000 min -1M-1) but essentially no reactivity (k < 1 min -1M-1) toward physiological thiols such as glutathione. The pharmacokinetic and pharmacodynamic properties of a prototype dihydroisoxazole inhibitor, 1b, were evaluated; in mice the compound showed good oral bioavailability, short serum half-life and efficient TG2 inhibition in small intestinal tissue, and low toxicity. It also showed excellent synergism with N,N′-bis(2-chloroethyl)-N-nitrosourea (BCNU, carmustine) against refractory glioblastoma tumors in mice. A fluorescent dihydroisoxazole inhibitor 5 facilitated microscopic visualization of TG2 endocytosis from the extracellular surface of HCT-116 cells. Together, these findings demonstrate the promise of dihydroisoxazole compounds as probes for the biology of TG2 and its role in human disease.",
author = "Kihang Choi and Matthew Siegel and Piper, {Justin L.} and Liya Yuan and Eun Cho and Pavel Strnad and Bishr Omary and Rich, {Keith M.} and Chaitan Khosla",
year = "2005",
month = "4",
day = "1",
doi = "10.1016/j.chembiol.2005.02.007",
language = "English",
volume = "12",
pages = "469--475",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Chemistry and biology of dihydroisoxazole derivatives

T2 - Selective inhibitors of human transglutaminase 2

AU - Choi, Kihang

AU - Siegel, Matthew

AU - Piper, Justin L.

AU - Yuan, Liya

AU - Cho, Eun

AU - Strnad, Pavel

AU - Omary, Bishr

AU - Rich, Keith M.

AU - Khosla, Chaitan

PY - 2005/4/1

Y1 - 2005/4/1

N2 - 3-Halo-4,5-dihydroisoxazoles are attractive warheads for the selective inhibition of nucleophilic active sites in biological systems. A series of 3-bromo-4,5-dihydroisoxazole compounds were prepared and tested for their ability to irreversibly inhibit human transglutaminase 2 (TG2), an enzyme that plays an important role in the pathogenesis of diverse disorders including Celiac Sprue and certain types of cancers. Several compounds showed high specificity for human TG2 (kinh/KI > 2000 min -1M-1) but essentially no reactivity (k < 1 min -1M-1) toward physiological thiols such as glutathione. The pharmacokinetic and pharmacodynamic properties of a prototype dihydroisoxazole inhibitor, 1b, were evaluated; in mice the compound showed good oral bioavailability, short serum half-life and efficient TG2 inhibition in small intestinal tissue, and low toxicity. It also showed excellent synergism with N,N′-bis(2-chloroethyl)-N-nitrosourea (BCNU, carmustine) against refractory glioblastoma tumors in mice. A fluorescent dihydroisoxazole inhibitor 5 facilitated microscopic visualization of TG2 endocytosis from the extracellular surface of HCT-116 cells. Together, these findings demonstrate the promise of dihydroisoxazole compounds as probes for the biology of TG2 and its role in human disease.

AB - 3-Halo-4,5-dihydroisoxazoles are attractive warheads for the selective inhibition of nucleophilic active sites in biological systems. A series of 3-bromo-4,5-dihydroisoxazole compounds were prepared and tested for their ability to irreversibly inhibit human transglutaminase 2 (TG2), an enzyme that plays an important role in the pathogenesis of diverse disorders including Celiac Sprue and certain types of cancers. Several compounds showed high specificity for human TG2 (kinh/KI > 2000 min -1M-1) but essentially no reactivity (k < 1 min -1M-1) toward physiological thiols such as glutathione. The pharmacokinetic and pharmacodynamic properties of a prototype dihydroisoxazole inhibitor, 1b, were evaluated; in mice the compound showed good oral bioavailability, short serum half-life and efficient TG2 inhibition in small intestinal tissue, and low toxicity. It also showed excellent synergism with N,N′-bis(2-chloroethyl)-N-nitrosourea (BCNU, carmustine) against refractory glioblastoma tumors in mice. A fluorescent dihydroisoxazole inhibitor 5 facilitated microscopic visualization of TG2 endocytosis from the extracellular surface of HCT-116 cells. Together, these findings demonstrate the promise of dihydroisoxazole compounds as probes for the biology of TG2 and its role in human disease.

UR - http://www.scopus.com/inward/record.url?scp=17844391272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844391272&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2005.02.007

DO - 10.1016/j.chembiol.2005.02.007

M3 - Article

C2 - 15850984

AN - SCOPUS:17844391272

VL - 12

SP - 469

EP - 475

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 4

ER -